Elite Pharmaceuticals, Inc. (OTCMKTS:ELTP - Get Free Report)'s stock price passed below its two hundred day moving average during trading on Friday . The stock has a two hundred day moving average of $0.47 and traded as low as $0.46. Elite Pharmaceuticals shares last traded at $0.49, with a volume of 831,291 shares trading hands.
Elite Pharmaceuticals Trading Up 0.0 %
The firm's 50-day simple moving average is $0.51 and its 200 day simple moving average is $0.48. The company has a debt-to-equity ratio of 0.12, a current ratio of 3.27 and a quick ratio of 1.90. The firm has a market capitalization of $512.81 million, a price-to-earnings ratio of -24.00 and a beta of 0.14.
Elite Pharmaceuticals (OTCMKTS:ELTP - Get Free Report) last posted its quarterly earnings results on Thursday, February 13th. The specialty pharmaceutical company reported ($0.01) EPS for the quarter. Elite Pharmaceuticals had a negative return on equity of 6.92% and a negative net margin of 25.70%.
About Elite Pharmaceuticals
(
Get Free Report)
Elite Pharmaceuticals, Inc, a specialty pharmaceutical company, engages in the development, manufacture, and sale of oral, controlled-release products, and generic pharmaceuticals. The company operates in two segments, Abbreviated New Drug Applications for Generic Pharmaceuticals and New Drug Applications for Branded Pharmaceuticals.
Read More
Before you consider Elite Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Elite Pharmaceuticals wasn't on the list.
While Elite Pharmaceuticals currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio?
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
